Prellis Biologics

Harnessing human diversity and AI to build next-generation medicines

San Francisco, United States · Founded 2016 · $49.5M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$49.5M
Last Round
$35.0M Series CAug 2022
Rounds
2

About

Prellis Biologics is a pre-IPO biotech company that harnesses AI and human immune diversity to develop next-generation antibody therapeutics. Its EXIS (Externalized Immune System) platform combines holographic bioprinting, fully human antibody discovery, and tightly integrated machine learning to identify antibody candidates from the full human immune repertoire with unparalleled speed and precision. The company partners with pharmaceutical companies to advance drug discovery across metabolic disease, inflammation, and oncology.

Summary

Prellis Biologics is a Healthcare company based in San Francisco, United States, founded in 2016. It has raised $49.5M in total across 2 rounds, most recently a $35.0M Series C round in Aug 2022. Investors include Celesta Capital and Avidity Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CAug 2022
$35.0M

Sign up to see all 2 rounds

Series B through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Prellis Biologics on Indexed.vc
<a href="https://indexed.vc/companies/prellis-biologics"><img src="https://indexed.vc/api/badge/company/prellis-biologics" alt="Prellis Biologics on Indexed.vc" width="260" height="76" /></a>